RayzeBio radiopharmaceutical therapeutics company with its main program in a Phase 3 clinical trial. Co.'s main drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing somatostatin receptor type 2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225. Co. is enrolling patients in a registrational Phase 3 clinical trial of RYZ101 for the treatment of gastroenteropancreatic neuroendocrine tumors in patients who have experienced progression of their cancer following treatment with Lu177 therapy. The RYZB average annual return since 2023 is shown above.
The Average Annual Return on the RYZB average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RYZB average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RYZB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|